Investor Overview

Corporate Profile
Histogenics is a regenerative medicine company focused on developing and commercializing products in the musculoskeletal segment of the marketplace. Our regenerative medicine platform combines expertise in cell processing, scaffolding, tissue engineering, bioadhesives and growth factors to provide solutions that can be utilized individually or in concert to treat musculoskeletal-related conditions. Our first investigational product candidate, NeoCart®, leverages our platform to provide an innovative treatment in the orthopedic space, specifically cartilage damage in the knee. For more information on Histogenics, please visit the company website at www.histogenics.com.
Stock Quote
HSGX (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$1.96
Change (%) Stock is Down 0.05 (2.49%)
Volume18,427
Data as of 09/25/17 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote

Recent NewsMore >>
DateTitle 
08/24/17Histogenics Corporation to Present at Upcoming Investor Conferences
WALTHAM, Mass., Aug. 24, 2017 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced that Company Management will be presenting at three upcoming conferences in September 2017.  Baird 2017 Global Healthcare Conference – New York, NY (September 6-7, 2017) Jonathan Lieber, Chief Financial Officer of Histogenics, will be presenting a corporat... 
Printer Friendly Version
08/10/17Histogenics Corporation Announces Second Quarter 2017 Financial and Operating Results
‒ Completed Enrollment in NeoCart® Phase 3 Clinical Trial ‒ ‒ Top-line Data and Potential BLA Filing Expected in Third Quarter of 2018 ‒ ‒ Defined Regulatory Pathway with Japan Pharmaceuticals and Medical Devices Agency ‒ ‒ Market Research in U.S. and Japan Points to Potential Large Markets with Significant Unmet Need ‒ WALTHAM, Mass., Aug. 10, 2017 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commerciali... 
Printer Friendly Version
07/27/17Histogenics Corporation to Announce Second Quarter 2017 Financial Results on August 10, 2017
WALTHAM, Mass., July 27, 2017 (GLOBE NEWSWIRE) -- Histogenics Corporation (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, announced it will release its financial and operational results for the quarter ended June 30, 2017, on August 10, 2017 before the market opens.  Histogenics’ management will host a conference call on Thursday, August 10, 2017 at 8:30 a.m. EDT.  A question-and-answer session will follow Histo... 
Printer Friendly Version
07/26/17Histogenics Corporation to Present at the 37th Annual Canaccord Genuity Growth Conference
WALTHAM, Mass., July 26, 2017 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced that Adam Gridley, President and Chief Executive Officer of Histogenics, will present at the 37th Annual Growth Conference on Wednesday, August 9, 2017 at 10:00 AM EDT at the InterContinental Boston in Boston, MA.  This presentation will be webcast live and may b... 
Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Contact Information

Histogenics Corporation
Phone: 781.547.7900
E-mail: InvestorRelations@histogenics.com

Featured Documents
View the Company Profile
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Histogenics Corp posts new information to the site. Just enter your e-mail address and click Submit.
 

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.